None listed
Conditions
Interventions
Medical Device : The subjects will be randomly assigned to either treatment group A, treatment group B, or a control group. All three groups will receive treatment as inpatients according to the clini
Sponsors
Catholic Kwandong University International St.Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are between 19 and 85 years of age 2. Patients who underwent proximal femoral fracture surgery 3. Patients whose proximal femoral fracture surgery was performed using a specific suturing technique · fasciorrhaphy were performed at 1cm intervals using Vicryl Plus Antibacterial Suture® #1, (ETHICON, Inc., Somerville, NJ). · The subcuticular continuous suture technique was performed using Vicryl 4-0 to maintain dermal junction without leaving suture marks. 4. Those who agreed to participate and signed a consent form after being informed of the purpose and particularities of the clinical trial
Exclusion criteria
Exclusion criteria: 1. Patients with a medical history of the formation of hypertrophic scars and keloids in the skin 2. Patients with a medical history of vitamin C and zinc deficiency 3. Patients who use steroids or smoke during post-surgery hospitalization 4. Patients with allergic dermatitis 5. Patients whose participation in the study is difficult due to skin troubles or diseases developed pre-surgery 6. Patients with connective tissue disorder or hypoalbuminemia 7. Patients with diabetes (HbA1c>8%) or high blood pressure (at least 160mmHg in systolic blood pressure or at least 100mmHg in diastolic pressure) that cannot be controlled with diet therapy or medication 8. Patients with renal dysfunction (the serum creatinine level is at least twice the upper limit of normal) or chronic renal failure 9. Patients with hepatic dysfunction (the AST or ALRT is at least three times the upper limit of normal) or liver cirrhosis 10. Patients with thyroid dysfunction (In this case, those who are deemed capable of controlling the disease with a stable dose of medication over a 12-week period before the screening and capable of maintaining the same condition during the study can participate.) 11. Patients with hematologic, cardiac, lung, neurological, or mental diseases, or other serious systemic disorders that are unlikely to enable them to perform the clinical study 12. Pregnant, expecting pregnant or breast-feeding women 13. Patients who are participating in another clinical trial 14. Other patients whose participation is deemed inappropriate by the person in charge of the clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vancouver scale for assessment of burn scar | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog Scale (VAS) ;Lab test (CRP (C-reactive protein), ESR (Erythrocyte Sedimentation Rate), WBC (White Blood Cell), procalcitonin) ;Redness degree and Dehiscence;Discharge amount ;Medication Amount;Incidence rate of postoperative complication;Adverse events | — |
Countries
Korea, Republic of
Contacts
Public ContactTae-Yong Park
Catholic Kwandong University
Outcome results
None listed